This trial is examining the effectiveness of CTX110, a treatment that modifies a patient’s own immune cells to treat relapsed or unresponsive non-Hodgkin lymphoma (NHL). The main outcome of this study is to see the number of patients that respond to treatment and side effects experienced. This study is recruiting in Nashville, Tennessee, and Westwood, Kansas, the United States.
NHL is a type of immune cell cancer. Some patients respond to treatment such as chemotherapy but the cancer returns and this is called relapsed NHL. Some patients do not respond to treatment and this is called refractory NHL. Healthy immune cells that detect cancers do not detect NHL cells. These cells are called T cells. CTX110 is a treatment where the T cells are taken from a patient with a B cell lymphoma and are being modified in the lab before they are injected back into the patient. The modified T cells should then detect cancer cells and kill them.
The purpose of this study is to see if CTX110 can be used to treat patients with NHL. The main outcomes of the study will be to see how effective the treatment is and what side effects patients experience.
Who are they looking for?
This study is recruiting 95 patients with relapsed or refractory NHL. Patients must be over 18 years old and have had at least two types of previous treatment. Patients must have good kidney, liver, heart and lung function. Patients of childbearing age must agree to use contraception for at least 12 months after treatment.
Patients who have received certain treatments such as CAR T cells or stem cell transplants cannot participate. Patients with a history of cancer in the brain or other brain disorders cannot participate. Patients with infections including HIV, Hepatitis B or C cannot participate. Patients who have received anti-cancer treatment 14 days before the trial cannot participate. Patients with an autoimmune disease cannot participate. Women who are pregnant or breastfeeding cannot participate.
How will it work
All patients in this study will receive CTX110 treatment. This will be given by an infusion into the vein after chemotherapy to kill cancer cells.
Patients will be monitored for 60 months to examine their response to the treatment and side effects experienced. Patients will also be monitored for 60 months to see how long the effects of treatment last, how long they survive and how long they survive without the cancer getting worse.